The historical rank and industry rank for Noile-Immune Biotech's Days Payable or its related term are showing as below:
During the past 6 years, Noile-Immune Biotech's highest Days Payable was 25459.22. The lowest was 11233.92. And the median was 19125.71.
TSE:4893's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.1 * Ranked among companies with meaningful Days Payable only.
Noile-Immune Biotech's Days Payable
stayed the same
from Jun. 2024 (0.00) to Dec. 2025 (0.00).
stayed the same
Noile-Immune Biotech Days Payable Related Terms
Noile-Immune Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Noile-Immune Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech (TSE:4893) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Noile-Immune Biotech and its competitors. Over the past decade, Noile-Immune Biotech's Days Payable has ranged from 11,233.92 to 25,459.22. According to the industry distribution chart, Noile-Immune Biotech ranks #999999 out of 700 companies in the Biotechnology industry.
Is Noile-Immune Biotech's Days Payable too high?
Noile-Immune Biotech's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 11,233.92 to a high of 25,459.22. Based on the distribution chart, Noile-Immune Biotech ranks #999999 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #999999 out of 700 companies for Days Payable. This places Noile-Immune Biotech in the lower half of its industry. The industry median Days Payable is 113.10. Historically, Noile-Immune Biotech's own Days Payable has ranged from 11,233.92 to 25,459.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Noile-Immune Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.35, compared to a current price of 円128.00 — trading 2842.5% above its estimated fair value. The current Days Payable is 0.00. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円128.00 is trading 2842.5% above its estimated GF Value™ of 円4.35.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Days Payable: 0.00
GF Value™: 円4.35 vs. price of 円128.00 (2842.5% above fair value)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score
Get the complete analysis for TSE:4893
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
